4-EPIOXYTETRACYCLINE | 79-57-2

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 抗真菌类药
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 四环素类
• 英文名称: 4-EPIOXYTETRACYCLINE
• 英文别名: (4R,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide；Oxytetracycline dihydrate；Oxytetracycline；(4S,4aR,5S,6S,12aS)-4-Dimethylamino-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide；4S-(4α,4aα,5a,5aα,6β,12aα)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-2-naphtacenecarboxamide；Oxytetracyclin；Oxy-tetracyclin
• CAS: 79-57-2；14206-58-7；22042-27-9；35259-39-3；65309-81-1；6153-64-6
• 化学式: C₂₂H₂₄N₂O₉
• 分子量: 460.441
• InChiKey: IWVCMVBTMGNXQD-CQFGZNOSSA-N

物化性质

• 熔点：
  181-182 °C
• 比旋光度：
  -216 º (c=1,0.1 M HCl)
• 溶解度：
  1M HCl：0.1 M 黄色至橙黄色，透明

计算性质

• 辛醇/水分配系数(LogP)：
  -1.24
• 重原子数：
  33.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  201.85
• 氢给体数：
  7.0
• 氢受体数：
  10.0

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S24/25,S26,S36/37/39
• 危险类别码：
  R36,R63
• WGK Germany：
  2
• 海关编码：
  30029090
• 危险品运输编号：
  NONH for all modes of transport
• RTECS号：
  QI7875000

制备方法与用途

生物活性

Oxytetracycline Dihydrate 是一种处方抗生素，干扰细菌产生必需蛋白质的能力。

靶点

HSV-1

Bacterial

Human Endogenous Metabolite

体外研究

Oxytetracycline is an important member of the bacterial aromatic polyketide family, which is a structurally diverse class of natural products. Oxytetracycline is synthesized by a type II polyketide synthase that generates the poly-beta-ketone backbone through successive decarboxylative condensation of malonyl-CoA extender units, followed by modifications by cyclases, oxygenases, transferases, and additional tailoring enzymes.

体内研究

The effects of administration a therapeutic dose of Oxytetracycline (82.8 mg/kg of bw to 1 % bw/day) for 10 days are species specific. Oxytetracycline increases the relative liver weight in Morone chrysops x M. saxatilis , the enzymatic activity of CYP3A4 in Ictalurus punctatus, protein expression of CYP3A4 in Oreochromis niloticus and depleted the hepatic CYP3A4 in the latter.
For Oxytetracycline, the limits are 100 μg/kg in muscle and milk, 200 μg/kg in egg, 300 μg/kg in liver and 600 μg/kg in kidney. Oxytetracycline (OTC) is administered to fish as medicated feed at concentrations ranging from 35 to 75 mg a.i kg-1 biomass day-1 for 7-14 days.

用途 

阻止aminoacyl-tRNA结合到30S亚单元上，抑制蛋白质合成（延长期）。 抗菌谱: 革兰氏阴性和阳性菌

反应信息

• 作为反应物：
  描述：

  三甲基氯硅烷 、 4-EPIOXYTETRACYCLINE 在 六甲基二硅氮烷 作用下， 以 吡啶 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  四环素研究。第三部分 四环素的三甲基甲硅烷基衍生物

  摘要：

  四环素和A环模型在吡啶中被三甲基氯硅烷和六甲基二硅氮烷转化为三甲基甲硅烷基衍生物，该衍生物易于溶解在普通溶剂中。这有助于使用nmr和ir光谱阐明四环素的分子结构。

  DOI：

  10.1039/j39700000636
• 作为产物：
  描述：

  oxytetracycline hydrochloride 生成 4-EPIOXYTETRACYCLINE
  参考文献：
  名称：

  RAUSCHENBACH, I.;ANGER, I.;LINDE, H.

  摘要：

  DOI：

文献信息

• TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES
  申请人：Paratek Pharmaceuticals, Inc.

  公开号：US20180016225A1

  公开（公告）日：2018-01-18

  Methods and compounds for treating diseases with tetracycline compounds having a target therapeutic activity are described.

  使用具有目标治疗活性的四环素化合物治疗疾病的方法和化合物被描述。
• Antibiotic preparation and use of the same in plants
  申请人：QUIMICA AGRONOMICA DE MEXICO, S. DE R.L. MI.

  公开号：EP0566291A1

  公开（公告）日：1993-10-20

  An antibiotic formulation comprising gentamicin, and optionally tetracycline or oxytetracycline, for use in plants.

  一种抗生素制剂，由庆大霉素和可选的四环素或土霉素组成，用于植物。
• POROUS SUBSTANCE AND PROCESS FOR PRODUCING THE SAME
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1354581A1

  公开（公告）日：2003-10-22

  A physiologically active porous substance of the present invention obtained by treating a physiologically active solid substance with a carbon dioxide in a supercritical or subcritical state or a liquid carbon dioxide has a significantly improved dissolution rate and can easily be handled.

  本发明通过用超临界或亚临界状态的二氧化碳或液态二氧化碳处理生理活性固体物质而获得的生理活性多孔物质，其溶解速率显著提高，且易于处理。
• Bacteria identification and antimicrobial susceptibility test
  申请人：MASTAPLEX LIMITED

  公开号：US10829796B2

  公开（公告）日：2020-11-10

  The present invention provides compositions, methods and kits for bacteria identification and anti-microbial susceptibility testing for the treatment of, for example, acute and chronic infections including infectious disease. The present invention is particularly useful in the identification of bacteria causing mastitis, and to antibiotic susceptibility testing to facilitate in the identification of an appropriate treatment for mastitis.

  本发明提供了用于细菌鉴定和抗微生物药敏试验的组合物、方法和试剂盒，以治疗包括传染病在内的急性和慢性感染。本发明尤其适用于鉴定引起乳腺炎的细菌，并进行抗生素药敏试验，以确定治疗乳腺炎的适当方法。
• Porous substances and methods for producing the same
  申请人：——

  公开号：US20040052854A1

  公开（公告）日：2004-03-18

  A physiologically active porous substance of the present invention obtained by treating a physiologically active solid substance with a carbon dioxide in a supercritical or subcritical state or a liquid carbon dioxide has a significantly improved dissolution rate and can easily be handled.

  本发明通过用超临界或亚临界状态的二氧化碳或液态二氧化碳处理生理活性固体物质而获得的生理活性多孔物质，其溶解速率显著提高，且易于处理。